CRO Pharmatest Services has announced two new services at the ASBMR annual meeting in Montreal, Canada.
The new offerings included a preclinical mouse model of osteogenesis imperfecta and clinical bone marker measurement.
Pharmatest offers preclinical efficacy services in the fields of oncology and skeletal diseases. In skeletal diseases, the company provides bone cell culture models and animal models of osteoporosis and osteoarthritis.
Pharmatest has now widened its portfolio of preclinical efficacy models in skeletal diseases by launching a mouse model of osteogenesis imperfecta (OI). The model utilises heterozygous (+/G610C) male mice that exhibit a variable form of OI (type IV).
CEO of Pharmatest Jussi Halleen comments: “The OI model that we are now launching is our first model of rare bone diseases, and it strengthens our position as a CRO offering preclinical efficacy models in skeletal diseases.”
Pharmatest has strong expertise in performing bone turnover marker measurements in its preclinical efficacy models. Pharmatest now launches clinical bone marker measurements that are performed using the iSYS automated platform of Immunodiagnostic Systems Plc (IDS).
Research director in the bone marker unit of Pharmatest Katja Fagerlund says: “We have a long history in collaborating with IDS and offering bone turnover marker measurements in our preclinical studies. We are now very excited to start offering also clinical bone marker measurements using the IDS-iSYS automated platform.”